The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity
https://doi.org/10.14341/probl201258134-38
Abstract
References
1. World Health Organization Obesity and overweight facts (удаленный доступ: http://www.who.int/mediacentre/factsheets/fs311/en/index.html] (accessed July 2005).
2. Бутрова С.А. Сибутрамин (меридиа) в лечении ожирения: опыт применения в России. Клин фарм и тер 2001; 10: 2: 71-74.
3. Rang H.P., Dale M.M., Ritter J.M., Moore P.K. Pharmacology (5th Ed.). Lovington (Edinburg) 2004; 394-403.
4. Cummings D.E., Schwartz M.W. Genetics and pathophysiology of human obesity. Ann Rev Med 2003; 54: 453-471.
5. Харкевич Д.А. Фармакология. М 2004; 350-351, 497-500.
6. Kopelman P.G., Grace C. New thoughts on managing obesity. Gut 2004; 53: 7: 1044-1053.
7. Labib M. acp Best Practice No 168. The investigation and management of obesity. J Clin Pathol 2003; 56: 1: 17-25.
8. Murphy K.G., Bloom S.R. Gut hormones in the control of appetite. Exp Physiol 2004; 89: 5: 507-516.
9. Payer J., Hainer V., Ondrejka P. et al. Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study) J Vnitr Lek 2004; 50: 11: 825-829.
10. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; Suppl 7: Suppl L: L32-L38.
11. Hainer V., Kabrnova K., Aldhoon B. et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann NY Acad Sci 2006; 1083: 252-269.
12. Luque C.A., Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002; 440: 2-3: 119-128.
13. Phelan S., Wadden T.A. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002; 10: 6: 560-574.
14. Kennedy G.C. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci 1953; 140: 901: 578-596.
15. Bray G.A., Ryan D.H., Gordon D. et al. A double-blind randomized placebo-controlled trial of sibutramine. Obestet Res 1996; 4: 3: 263-270.
16. James W.P, Astrup A., Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 9248: 2119-2125.
17. Philip W., James T., Ian D. et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med 2010; 363: 905-917.
18. Bjorntorp P., Holm J., Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med 1999; 16: 5: 373-383.
19. Дедов И.И., Мельниченко Г.А. Ожирение. Руководство для врачей. М 2004; 52-53.
20. Harris R.B., Kasser T.R., Martin R.J. Dynamics of recovery of body composition after overfeeding, food restriction or starvation of mature female rats. J Nutr 1986; 116: 12: 2536-2546.
21. Gibbs J., Young R.C., Smith G.P. Cholecystokinin decreases food intake in rats. J Comp Phys Psychol 1973; 84: 3: 488-495.
Review
For citations:
Vlasova I.I., Ametov A.S. The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity. Problems of Endocrinology. 2012;58(1):34-38. https://doi.org/10.14341/probl201258134-38
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
